{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:31:11Z","timestamp":1792103471963,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21NS123685"],"award-info":[{"award-number":["R21NS123685"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA276942"],"award-info":[{"award-number":["R01CA276942"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R01NS106173-01A1"],"award-info":[{"award-number":["1R01NS106173-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite multimodal therapy of surgical resection, radiation, and chemotherapy, glioblastoma patients show a dismal prognosis. Protein Arginine Methyltransferase 5 (PRMT5) is overexpressed in glioblastoma, and its inhibition imparts an anti-tumor effect. Tumor cells invariably develop resistance to Temozolomide (TMZ), the standard chemotherapeutic agent for glioblastoma. However, the mechanistic role of PRMT5 in treatment-resistant glioblastoma is unknown. Patient-derived glioma stem-like cells (GSCs), treated with PRMT5 inhibitor (LLY-283) or transfected with PRMT5-target-specific siRNA, were treated with TMZ and subjected to in vitro functional and mechanistic studies. The intracranial mouse xenograft model was used to test the in vivo antitumor efficacy of combination treatment. We found that PRMT5 inhibition increased the cytotoxic effect of TMZ in GSCs. Unbiased transcriptomic profiling revealed negative enrichment of DNA damage repair pathways, with prominent suppression of the Fanconi anemia (FA) pathway. PRMT5 inhibition abrogated the TMZ-induced G2\/M cell cycle arrest. Importantly, combination treatment increased the DNA double-strand breaks (\u03b3H2AX foci) and enhanced the DNA damage (comet assay). Specifically, the LLY-283 treatment blocked the FA pathway-mediated homologous recombination repair in GSCs. In vivo, the LLY-283 and TMZ combination significantly curbs tumor growth and prolongs the survival of tumor-bearing mice. Furthermore, compared to monotherapy, there was a significant reduction in the proliferation marker Ki-67, while the apoptosis marker cleaved caspase 3 and the DNA damage response marker \u03b3H2AX were upregulated. Collectively, these findings identify PRMT5 as a critical regulator of the FA pathway in glioblastoma and demonstrate that PRMT5 inhibition potentiates TMZ efficacy by disrupting FA-dependent homologous recombination repair, indicating that the combination of PRMT5 inhibition and TMZ could be a novel therapeutic strategy for glioblastoma.<\/jats:p>","DOI":"10.1038\/s41419-026-08739-5","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:18:20Z","timestamp":1776230300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-6540","authenticated-orcid":false,"given":"Shumpei","family":"Onishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridharan","family":"Jayamohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashis","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Ertekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-0081","authenticated-orcid":false,"given":"Sara A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-7286","authenticated-orcid":false,"given":"Kimberly A.","family":"Rivera-Caraballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Walbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayu","family":"Sisay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Maric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Elkahloun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kory","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Heiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-4783","authenticated-orcid":false,"given":"Sangamesh G.","family":"Kumbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balveen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-3932","authenticated-orcid":false,"given":"Gangadhara R.","family":"Sareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-6918","authenticated-orcid":false,"given":"Yeshavanth Kumar","family":"Banasavadi-Siddegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"8739_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"8739_CR2","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306\u201316.","journal-title":"JAMA"},{"key":"8739_CR3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/annonc\/mdx169","volume":"28","author":"MA Qazi","year":"2017","unstructured":"Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol : J Eur Soc Med Oncol. 2017;28:1448\u201356.","journal-title":"Ann Oncol : J Eur Soc Med Oncol"},{"key":"8739_CR4","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.1114033109","volume":"109","author":"NJ Szerlip","year":"2012","unstructured":"Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA. 2012;109:3041\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8739_CR5","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1101\/gad.261982.115","volume":"29","author":"JD Lathia","year":"2015","unstructured":"Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015;29:1203\u201317.","journal-title":"Genes Dev"},{"key":"8739_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756\u201360.","journal-title":"Nature"},{"key":"8739_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2647-9","volume":"16","author":"A Balbous","year":"2016","unstructured":"Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, et al. A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells. BMC Cancer. 2016;16:604.","journal-title":"BMC Cancer"},{"key":"8739_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.molonc.2014.08.003","volume":"9","author":"R Carruthers","year":"2015","unstructured":"Carruthers R, Ahmed SU, Strathdee K, Gomez-Roman N, Amoah-Buahin E, Watts C, et al. Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Mol Oncol. 2015;9:192\u2013203.","journal-title":"Mol Oncol"},{"key":"8739_CR9","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/0008-5472.CAN-14-3790","volume":"75","author":"SU Ahmed","year":"2015","unstructured":"Ahmed SU, Carruthers R, Gilmour L, Yildirim S, Watts C, Chalmers AJ. Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Res. 2015;75:4416\u201328.","journal-title":"Cancer Res"},{"key":"8739_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/cdd.2013.136","volume":"21","author":"M Venere","year":"2014","unstructured":"Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2014;21:258\u201369.","journal-title":"Cell Death Differ"},{"key":"8739_CR11","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-13-0884","volume":"74","author":"F Yan","year":"2014","unstructured":"Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res. 2014;74:1752\u201365.","journal-title":"Cancer Res"},{"key":"8739_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11060-014-1419-0","volume":"118","author":"X Han","year":"2014","unstructured":"Han X, Li R, Zhang W, Yang X, Wheeler CG, Friedman GK, et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J Neurooncol. 2014;118:61\u201372.","journal-title":"J Neurooncol"},{"key":"8739_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/onc.2016.199","volume":"36","author":"YK Banasavadi-Siddegowda","year":"2017","unstructured":"Banasavadi-Siddegowda YK, Russell L, Frair E, Karkhanis VA, Relation T, Yoo JY, et al. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells. Oncogene. 2017;36:263\u201374.","journal-title":"Oncogene"},{"key":"8739_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/neuonc\/nox206","volume":"20","author":"YK Banasavadi-Siddegowda","year":"2018","unstructured":"Banasavadi-Siddegowda YK, Welker AM, An M, Yang X, Zhou W, Shi G, et al. PRMT5 as a druggable target for glioblastoma therapy. Neuro Oncol. 2018;20:753\u201363.","journal-title":"Neuro Oncol"},{"key":"8739_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21204-5","volume":"12","author":"P Sachamitr","year":"2021","unstructured":"Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun. 2021;12:979.","journal-title":"Nat Commun"},{"key":"8739_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102264","volume":"52","author":"KJ Briggs","year":"2025","unstructured":"Briggs KJ, Cottrell KM, Tonini MR, Tsai A, Zhang M, Whittington DA, et al. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers. Transl Oncol. 2025;52:102264.","journal-title":"Transl Oncol"},{"key":"8739_CR17","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.molcel.2017.01.019","volume":"65","author":"TL Clarke","year":"2017","unstructured":"Clarke TL, Sanchez-Bailon MP, Chiang K, Reynolds JJ, Herrero-Ruiz J, Bandeiras TM, et al. PRMT5-dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination. Mol Cell. 2017;65:900\u201316 e7.","journal-title":"Mol Cell"},{"key":"8739_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00018-024-05154-x","volume":"81","author":"YJ Wang","year":"2024","unstructured":"Wang YJ, Cao JB, Yang J, Liu T, Yu HL, He ZX, et al. PRMT5-mediated homologous recombination repair is essential to maintain genomic integrity of neural progenitor cells. Cell Mol Life Sci. 2024;81:123.","journal-title":"Cell Mol Life Sci"},{"key":"8739_CR19","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","volume":"24","author":"PJ Hamard","year":"2018","unstructured":"Hamard PJ, Santiago GE, Liu F, Karl DL, Martinez C, Man N, et al. PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. Cell Rep. 2018;24:2643\u201357.","journal-title":"Cell Rep"},{"key":"8739_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.100750","volume":"23","author":"JL Owens","year":"2020","unstructured":"Owens JL, Beketova E, Liu S, Tinsley SL, Asberry AM, Deng X, et al. PRMT5 cooperates with pICln to function as a master epigenetic activator of DNA double-strand break repair genes. iScience. 2020;23:100750.","journal-title":"iScience"},{"key":"8739_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s42003-020-01157-z","volume":"3","author":"JW Hwang","year":"2020","unstructured":"Hwang JW, Kim SN, Myung N, Song D, Han G, Bae GU, et al. PRMT5 promotes DNA repair through methylation of 53BP1 and is regulated by Src-mediated phosphorylation. Commun Biol. 2020;3:428.","journal-title":"Commun Biol"},{"key":"8739_CR22","first-page":"513","volume":"19","author":"R Ortiz","year":"2021","unstructured":"Ortiz R, Perazzoli G, Cabeza L, Jimenez-Luna C, Luque R, Prados J, et al. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol. 2021;19:513\u201337.","journal-title":"Curr Neuropharmacol"},{"key":"8739_CR23","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierzanski","year":"2024","unstructured":"Jezierzanski M, Nafalska N, Stopyra M, Furgol T, Miciak M, Kabut J, et al. Temozolomide (TMZ) in the treatment of glioblastoma multiforme-a literature review and clinical outcomes. Curr Oncol. 2024;31:3994\u20134002.","journal-title":"Curr Oncol"},{"key":"8739_CR24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","volume":"488","author":"J Chen","year":"2012","unstructured":"Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522\u20136.","journal-title":"Nature"},{"key":"8739_CR25","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/stem.2703","volume":"35","author":"F Orzan","year":"2017","unstructured":"Orzan F, De Bacco F, Crisafulli G, Pellegatta S, Mussolin B, Siravegna G, et al. Genetic evolution of glioblastoma stem-like cells from primary to recurrent tumor. Stem Cells. 2017;35:2218\u201328.","journal-title":"Stem Cells"},{"key":"8739_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-018-0618-0","volume":"11","author":"H Li","year":"2018","unstructured":"Li H, Chen L, Li JJ, Zhou Q, Huang A, Liu WW, et al. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3\/Bcl2 signaling pathway. J Hematol Oncol. 2018;11:70.","journal-title":"J Hematol Oncol"},{"key":"8739_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","volume":"23","author":"ES Newlands","year":"1997","unstructured":"Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35\u201361.","journal-title":"Cancer Treat Rev"},{"key":"8739_CR28","first-page":"5843","volume":"61","author":"Y Hirose","year":"2001","unstructured":"Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 2001;61:5843\u20139.","journal-title":"Cancer Res"},{"key":"8739_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00109-006-0153-2","volume":"85","author":"CC Chen","year":"2007","unstructured":"Chen CC, Taniguchi T, D\u2019Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med (Berl). 2007;85:497\u2013509.","journal-title":"J Mol Med (Berl)"},{"key":"8739_CR30","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1158\/1541-7786.MCR-21-0093","volume":"19","author":"C Du","year":"2021","unstructured":"Du C, Li SW, Singh SX, Roso K, Sun MA, Pirozzi CJ, et al. Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization. Mol Cancer Res. 2021;19:2046\u201356.","journal-title":"Mol Cancer Res"},{"key":"8739_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nop020","volume":"12","author":"AL Rivera","year":"2010","unstructured":"Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12:116\u201321.","journal-title":"Neuro Oncol"},{"key":"8739_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003.","journal-title":"N Engl J Med"},{"key":"8739_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/neuonc\/nor010","volume":"13","author":"SC Short","year":"2011","unstructured":"Short SC, Giampieri S, Worku M, Alcaide-German M, Sioftanos G, Bourne S, et al. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro Oncol. 2011;13:487\u201399.","journal-title":"Neuro Oncol"},{"key":"8739_CR34","doi-asserted-by":"publisher","first-page":"e27183","DOI":"10.1371\/journal.pone.0027183","volume":"6","author":"S Quiros","year":"2011","unstructured":"Quiros S, Roos WP, Kaina B. Rad51 and BRCA2-New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS ONE. 2011;6:e27183.","journal-title":"PLoS ONE"},{"key":"8739_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.stemcr.2016.12.005","volume":"8","author":"HO King","year":"2017","unstructured":"King HO, Brend T, Payne HL, Wright A, Ward TA, Patel K, et al. RAD51 is a selective DNA repair target to radiosensitize glioma stem cells. Stem Cell Rep. 2017;8:125\u201339.","journal-title":"Stem Cell Rep"},{"key":"8739_CR36","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41388-024-03264-1","volume":"44","author":"MS Gillespie","year":"2025","unstructured":"Gillespie MS, Chiang K, Regan-Mochrie GL, Choi SY, Ward CM, Sahay D, et al. PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells. Oncogene. 2025;44:862\u201376.","journal-title":"Oncogene"},{"key":"8739_CR37","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/neuonc\/noad018","volume":"25","author":"S Alejo","year":"2023","unstructured":"Alejo S, Palacios BE, Venkata PP, He Y, Li W, Johnson JD, et al. Lysine-specific histone demethylase 1A (KDM1A\/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro Oncol. 2023;25:1249\u201361.","journal-title":"Neuro Oncol"},{"key":"8739_CR38","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8739_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373.","journal-title":"Nat Genet"},{"key":"8739_CR40","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/neuonc\/noab014","volume":"23","author":"Y Otani","year":"2021","unstructured":"Otani Y, Sur HP, Rachaiah G, Namagiri S, Chowdhury A, Lewis CT, et al. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma. Neuro Oncol. 2021;23:1481\u201393.","journal-title":"Neuro Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08739-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:06:57Z","timestamp":1779354417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08739-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8739"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08739-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We have no conflict of interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, the author used ChIRP (Chatbot for Intramural Research Program) software of NIH to reduce the word count of the introduction and results sections of the manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"505"}}